Related Experiment Videos
Abstract:
The preceding review of bronchogenic carcinoma and our own experience with lung cancer patients, indicate that long-term survival of these patients has only minimally improved. Advanced lung cancer does not significantly respond to the current treatment armamentarium, but present research and clinical trials of such new treatments as immunotherapy and interferon therapy may give hope for the future. At present our biggest weapon against lung cancer is still the elimination of cigarette smoking. Until we achieve this unlikely goal or greatly improve our success in treating the disease, we will need to continue our commitment to assist the patient with lung cancer in achieving the highest quality of life.
Insights
Lung cancer survival rates remain low, with advanced stages unresponsive to current treatments. Future hope lies in novel therapies like immunotherapy, but smoking cessation is key for lung cancer prevention.
Area of Science:
- Oncology
- Pulmonology
Background:
- Bronchogenic carcinoma (lung cancer) survival rates show minimal improvement.
- Advanced lung cancer exhibits limited response to existing treatment options.
Purpose of the Study:
- To review the current state of lung cancer treatment and survival.
- To highlight the potential of emerging therapies and preventive measures.
Main Methods:
- Review of existing literature on bronchogenic carcinoma.
- Analysis of clinical experience with lung cancer patients.
Main Results:
- Long-term survival for lung cancer patients has seen only slight improvement.
- Current treatments are largely ineffective for advanced lung cancer.
Conclusions:
- Novel treatments like immunotherapy and interferon therapy offer future promise.
- Cigarette smoking elimination remains the most critical weapon against lung cancer.
- Improving quality of life for lung cancer patients is an ongoing priority.